Clinical trials: Acute Ischemic Stroke AIS, open to volunteers
Acute Ischemic Stroke (AIS)
Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial
Acute ischemic stroke caused by blockage of a large artery in the brain is one of the leading causes of death and long-term disability worldwide.
- Trial name
- TOPAZ (NCT07734792)
- Testing
- Tirzepatide, Standard Medical Care (SMC)
- Where
- China
- Volunteers
- 726 people
- Sponsor
- yifang zhu
Stroke, Acute Ischemic, Endovascular Thrombectomy
ACT-GLOBAL IA Thrombolysis(ACT-REACT-004)Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
Study Design and Duration: This domain will be conducted as part of ACT-GLOBAL platform trial and will have the nested domain name of REACT.
- Conditions
- Stroke, Acute Ischemic, Endovascular Thrombectomy, Acute Ischemic Stroke AIS
- Trial name
- ACT-REACT (NCT07687056)
- Testing
- Tenecteplase or Alteplase- depending upon availability at each treating centre, Control
- Where
- 13 sites in Australia, Canada
- Volunteers
- 1,500 people
- Sponsor
- University of Calgary
Acute Ischemic Stroke
Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke
This phase II clinical study is designed to evaluate the safety and efficacy of LT3001 in the treatment of acute ischemic stroke
- Trial name
- NCT05686642
- Testing
- LT3001 Drug:high dose, LT3001 Drug:low dose
- Where
- 28 sites in China
- Volunteers
- 300 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Acute Ischemic Stroke AIS, Stroke Acute
ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
This domain has a prospective, randomized, controlled, open-label, parallel group with blinded endpoint assessment (PROBE) design.
- Conditions
- Acute Ischemic Stroke AIS, Stroke Acute, Stroke, Acute, Stroke Ischemic
- Trial name
- ACT-WHEN (NCT06320431)
- Testing
- Tenecteplase
- Where
- 24 sites in Australia, Canada
- Volunteers
- 4,000 people
- Sponsor
- University of Calgary
AIS
A Multicentre, Randomised, Double-blind, Placebo-parallel Controlled Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of BXOS110 Injection in the Treatment of Acute Ischaemic Stroke Within 3 Hours of Onset.
The purpose of this study was to evaluate the efficacy of early administration of BXOS110 for injection in reducing overall disability in patients with acute ischaemic stroke
- Trial name
- NCT07520565
- Testing
- BXOS110
- Where
- 9 sites in China
- Volunteers
- 1,112 people
- Sponsor
- Biocells (Beijing) Biotech Co.,Ltd
Acute Ischemic Stroke
A Study to Evaluate the Intracranial Arterial Recanalization With Multiple Doses of LT3001 Drug Product in AIS Participant
This is a phase II, open-label, single-arm, exploratory study to evaluate the intracranial arterial recanalization of multiple doses of LT3001 drug product in participant with acute ischemic stroke (AIS)
- Trial name
- NCT07890298
- Testing
- LT3001 Drug Product
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- Lumosa Therapeutics Co., Ltd.
Thrombosis, Acute Ischemic Stroke (AIS)
Intravenous Thrombolytic Therapy for Acute Ischemic Stroke Patients with Low NIHSS and Non-disabling Deficits
Minor stroke is considered an acute ischemic stroke (AIS) that has a National Institute of Health Stroke Scale (NIHSS) score ≤ 5 points.
- Trial name
- ALLOW (NCT06115070)
- Testing
- Intravenous thrombolysis (alteplase and other guideline-recommended thrombolytic agents)
- Where
- China
- Volunteers
- 390 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Acute Ischemic Stroke
Safety and Preliminary Efficacy of Hibernation-Like Therapy (Chlorpromazine and Promethazine) in Patients With Acute Ischemic Stroke (AIS) Eligible for Reperfusion Therapy.
This is a single-center, dose-escalation and dose-expansion Phase I study designed to evaluate the safety of hibernation-like therapy (Chlorpromazine and Promethazine, C+P) and observe improvements in infarct volume in patients…
- Trial name
- CHILL-S (NCT07364344)
- Testing
- Hibernation-like Therapy (Chlorpromazine and Promethazine, C+P)
- Volunteers
- 57 people
- Sponsor
- Ji Xunming,MD,PhD
Acute Ischemic Stroke AIS
Balloon Guide Versus Conventional Guide Catheter in Stroke Thrombectomy
The purpose of this clinical trial is to study the two main types of approaches used in stroke thrombectomy and to investigate if one approach is more effective than the other, as this is currently not known.
- Trial name
- 2Guide (NCT07085390)
- Testing
- Use of a Balloon Guide Catheter, Use of a Conventional (non-balloon) Guide Catheter
- Where
- 2 sites in United States
- Volunteers
- 186 people
- Sponsor
- University of South Florida
Acute Ischemic Stroke, Active Cancer
Acute Ischemic Stroke in Patients With Active Cancer
The goal of this multicenter prospective observational study, conducted at 24 hospitals in Japan, is to learn about recurrent ischemic stroke in people with active cancer who develop acute ischemic stroke.
- Trial name
- CAT-AIS (NCT07819526)
- Where
- Japan
- Volunteers
- 500 people
- Sponsor
- Osaka University
Stroke
Comparison Influence to Prognosis of CTP and MRP in AIS Patients
Acute ischemia stroke (AIS) is the leading cause of death in China. Thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) has been proven to reduce disability in AIS patients within 4.5 hours after symptom…
- Trial name
- NCT03367286
- Testing
- inspection mode
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Acute Ischemic Stroke From Large Vessel Occlusion
HBO After Thrombectomy for AIS With LVO
The purpose of this RCT trial is to evaluate whether the sequential hyperbaric oxygen therapy can improve the 90-day functional outcome in patients with acute large vessel occlusion ischemic stroke after endovascular treatment.
- Trial name
- NCT07626450
- Testing
- Hyperbaric oxygen therapy plus standard medical treatment, Standard medical treatment
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Beijing Tiantan Hospital
AIS, Stroke
Endovascular Treatment for Acute Large Vessel Occlusion With Ultra-Large Ischemic Core
an investigator initiated, prospective, multicenter, randomized, open-label, blinded endpoint trial (PROBE)
- Trial name
- LARGE CORE-MT (NCT07791810)
- Testing
- Patients assigned to the EVT group should undergo EVT as soon as possible, followed by BMM according to the current EVT guidelines., The medical group receives BMM alone. EVT is not performed in the medical group.
- Where
- China
- Volunteers
- 450 people
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Endovascular Therapy, Acute Ischemic Stroke
Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke With Occlusion of the M2 Segment of Middle Cerebral Artery
RESCUE-M2O trial is a prospective, open label, blinded endpoint (PROBE), two-arm, randomized, controlled, post-market study to assess the efficacy and safety of endovascular therapy for acute ischemic stroke with occlusion of the…
- Conditions
- Endovascular Therapy, Acute Ischemic Stroke, Acute Ischemic Stroke (AIS) Related to a Distal Occlusion
- Trial name
- NCT07347665
- Testing
- Endovascular therapy
- Where
- 3 sites in Japan, Thailand and 1 more
- Volunteers
- 200 people
- Sponsor
- Hyogo Medical University
Acute Ischemic Stroke AIS
Palmitoylethanolamide and Luteolin in Patients with Acute Ischemic Stroke
Acute ischemic stroke is caused by reduced blood supply to the brain associated with neuroinflammation. This mechanism contributes to acute neuronal death and persists even after reopening of the closed vessel, with consequent…
- Trial name
- NCT06777680
- Testing
- co-ultramicronized Palmitoylethanolamide + Luteolin (770 mg), Thrombectomy
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Ospedali Riuniti Trieste
Acute Ischemic Stroke
Angong Niuhuang Pills With Different Bovine Bezoar Formulation Sources in the Treatment of AIS
This study is a single-center, open-label, controlled clinical trial that prospectively enrolls 100 participants (40 in the Z11020076 group, 40 in the Z20063878 group, and 20 in the blank control group) to collect clinical data…
- Trial name
- NCT06883110
- Testing
- Z11020076, Z20063878
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Tongji Hospital
Acute Ischemic Stroke
Human Placenta-derived 3D Mesenchymal Stem Cells(Guojianqingke)
This is a Phase I/IIa clinical trial evaluating human placental-derived 3D mesenchymal stem cell (MSC) injection in patients with acute ischemic stroke (AIS).
- Trial name
- 3D MSC - QK01 (NCT07635758)
- Testing
- Human Placenta-derived 3D Mesenchymal Stem Cells (Guojiangqingke)
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Chinese PLA General Hospital
Acute Ischemic Stroke AIS, Cerebral Arterial Disease
Pulse Endovascular ReperFUSION for Acute Ischemic Stroke
Prospective, multi-center, single-arm early feasibility study enrolling a minimum of 15 subjects at up to a minimum of 3 active investigational sites in the United States.
- Trial name
- PERFUSION AIS (NCT06052969)
- Testing
- Pulse NanoMED System
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Euphrates Vascular, Inc.
Acute Ischemic Stroke (AIS)
Acute Ischemic Stroke Involves Significant Inflammatory Response. This Prospective Cohort Study Evaluates the Predictive Value of Monocyte-, Neutrophil-, and Leukocyte-to-albumin Ratios for Stroke Severity and Functional Outcome Using NIHSS at Admission and Modified Rankin Scale During Follow-up.
Acute Ischemic Stroke is a leading cause of mortality and long-term disability worldwide. Increasing evidence suggests that systemic inflammation plays a significant role in the pathophysiology and progression of ischemic brain…
- Trial name
- ALARMS (NCT07471061)
- Volunteers
- 60 people
- Sponsor
- Sohag University
Acute Ischemic Stroke
Safety and Efficacy of J147 in Acute Ischemic Stroke
The goal of this clinical trial is to find out if the drug J147 improves outcomes for persons who have had an ischemic stroke. It also will learn about the safety of J147 when given by injection to stroke patients.
- Trial name
- JUMPSTART (NCT07430917)
- Testing
- J147 Emulsion for Injection
- Where
- 5 sites in United States
- Volunteers
- 196 people
- Sponsor
- Abrexa Pharmaceuticals, Inc.